Citing economic conditions, Thomson Reuters has suspended efforts to sell its health care business lines.

The New York-based vendor announced in June 2011 it would divest its health operations and use the proceeds to invest in its core markets including legal, tax and accounting, science and intellectual property, financial services, and media. In a Dec. 22 statement, Thomson Reuters said global economic conditions have become more challenging and does not envision getting an offer of fair value for the health business. “Thomson Reuters is committed to continuing to invest in and grow the health care business until improved market conditions allow the company to complete a divestiture at attractive terms.”

Thomson Reuters’ health care business includes provider clinical decision support such as Micromedex, clinical benchmarking and regulatory reporting, data analytics including the MarketScan research databases, payer fraud and abuse management and cost control applications, and the Medical Episode Grouper methodology to enable government agencies to evaluate provider performance.

The health care unit had revenue of approximately $450 million in 2010 and an operating margin of around 19 percent, according to the company.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access